ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortium
ALK rearrangement has been found in 9.6% of lung cancer patients tested in the Lung Cancer Mutation Consortium, and MET amplification in another 4.1%, reflecting how many patients might benefit from targeted therapies such ...
Jul 5, 2011
0
0